147 related articles for article (PubMed ID: 24715227)
1. The preventive misconception: experiences from CAPRISA 004.
Dellar RC; Abdool Karim Q; Mansoor LE; Grobler A; Humphries H; Werner L; Ntombela F; Luthuli L; Abdool Karim SS
AIDS Behav; 2014 Sep; 18(9):1746-52. PubMed ID: 24715227
[TBL] [Abstract][Full Text] [Related]
2. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
[TBL] [Abstract][Full Text] [Related]
3. Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
Mansoor LE; Abdool Karim Q; Yende-Zuma N; MacQueen KM; Baxter C; Madlala BT; Grobler A; Abdool Karim SS
AIDS Behav; 2014 May; 18(5):811-9. PubMed ID: 24643315
[TBL] [Abstract][Full Text] [Related]
4. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
5. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
7. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
8. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
9. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
[TBL] [Abstract][Full Text] [Related]
10. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Mngadi KT; Maarschalk S; Grobler AC; Mansoor LE; Frohlich JA; Madlala B; Ngcobo N; Abdool Karim SS; Abdool Karim Q
AIDS Behav; 2014 May; 18(5):849-54. PubMed ID: 24633715
[TBL] [Abstract][Full Text] [Related]
11. Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Karim QA; Baxter C; Karim SA
BJOG; 2014 Oct; 121 Suppl 5(0 5):53-61. PubMed ID: 25335841
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
13. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral vaginal gel shows promise against HIV.
Baleta A
Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
[No Abstract] [Full Text] [Related]
15. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
[TBL] [Abstract][Full Text] [Related]
16. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
17. Predicting product adherence in a topical microbicide safety trial in Pune, India.
Tolley EE; Tsui S; Mehendale S; Weaver MA; Kohli R
AIDS Behav; 2012 Oct; 16(7):1808-15. PubMed ID: 21877203
[TBL] [Abstract][Full Text] [Related]
18. The North Carolina contribution to the CAPRISA 004 study: the Global Health Initiative in action.
Cates W; Kashuba AD
N C Med J; 2010; 71(5):490-1. PubMed ID: 21473558
[No Abstract] [Full Text] [Related]
19. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
[TBL] [Abstract][Full Text] [Related]
20. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]